Europe Cancer Supportive Care Products Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 5,653.60 Million |
 Market Size (Forecast Year) |
USD 7,891.71 Million |
 CAGR |
% |
| Major Markets Players |
欧洲癌症支持护理产品市场，按药物类型（粒细胞集落刺激因子 (GCSF)、促红细胞生成素刺激剂 (ESA'S)、阿片类镇痛药、单克隆抗体、非甾体抗炎药 (NSAID)、双膦酸盐、止吐药、抗组胺药等）、类型（品牌药和仿制药）、癌症类型（肺癌、乳腺癌、前列腺癌、肝癌、膀胱癌、白血病、黑色素瘤、卵巢癌和其他癌症）、最终用户（医院、诊所、医院和学术机构等）、分销渠道（医院药房、零售药房和复合药房）、国家（德国、英国、法国、意大利、西班牙、荷兰、俄罗斯、瑞士、土耳其、欧洲其他地区）行业趋势和预测到 2028 年
市场分析和见解：欧洲癌症支持护理产品市场
预计癌症支持护理产品市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场将以 4.4% 的复合年增长率增长，预计将从 2020 年的 56.536 亿美元达到 2028 年的 78.9171 亿美元。先进和发达的医疗保健系统是预测期内推动癌症支持护理产品需求的主要驱动力。
推动癌症支持护理产品市场增长的主要因素是政府加大力度控制癌症扩散，而阻碍癌症支持护理产品市场增长的因素是与癌症支持护理产品相关的副作用。主要市场参与者的合作和收购为全球癌症支持护理产品市场的增长提供了机会。
癌症支持护理产品市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
癌症支持护理产品市场范围和市场规模
癌症支持护理产品市场根据药物类型、类型、癌症类型、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据药物类型，癌症支持护理产品市场细分为粒细胞集落刺激因子 (GCSF)、促红细胞生成素刺激剂 (ESA)、阿片类镇痛药、单克隆抗体、非甾体抗炎药 (NSAID)、双膦酸盐、止吐药、抗组胺药等。2021 年，粒细胞集落刺激因子 (GCSF) 细分市场在癌症支持护理产品市场中占据主导地位，因为它刺激骨髓并产生干细胞以及粒细胞并将其排入血液。此外，粒细胞集落刺激因子 (GCSFS) 主要用于治疗和治愈因癌症化疗治疗引起的中性粒细胞减少症。
- 根据类型，癌症支持护理产品市场分为品牌药和仿制药。2021 年，仿制药占据癌症支持护理产品市场的主导地位，因为它具有成本效益、易于获取，并且主要由医生推荐用于癌症支持护理产品疾病。
- 根据癌症类型，癌症支持护理产品市场细分为肺癌、乳腺癌、前列腺癌、肝癌、膀胱癌、白血病、黑色素瘤、卵巢癌和其他癌症。2021 年，由于发达国家和发展中国家民众吸烟习惯的增加，肺癌领域在癌症支持护理产品市场占据主导地位。
- 根据最终用户，癌症支持护理产品市场分为医院、诊所、医院和学术机构等。2021 年，医院部门在癌症支持护理产品市场中占据主导地位，因为它为患者提供最好的医疗服务。此外，医院是癌症患者的主要医疗服务提供者。
- 根据分销渠道，癌症支持护理产品市场分为医院药房、零售药房和配药药房。2021 年，医院药房部门在癌症支持护理产品市场中占据主导地位，因为大多数药品都是通过医院药房采购的。处方药的日益普及也推动了癌症支持护理产品市场的增长。
欧洲癌症支持护理产品市场国家级分析
对癌症支持护理产品市场进行了分析，并按国家、药物类型、类型、癌症类型、最终用户和分销渠道提供了市场规模信息，如上所述。
癌症支持护理产品市场报告涵盖的国家包括英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、土耳其和欧洲其他国家。
由于欧洲拥有高科技医疗基础设施，且医疗支出不断增加，预计欧洲将在 2021 年至 2028 年预测期内保持高增长率。随着欧洲肿瘤产品研发活动的不断增加，德国在欧洲市场占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
制造商的战略举措为癌症支持护理产品市场参与者创造了新的机遇
癌症支持护理产品市场还为您提供每个国家增长的详细市场分析。此外，它还提供有关亚太地区癌症支持护理产品市场参与者之间的癌症支持护理产品销售、合作伙伴关系、收购、分销协议增长的详细数据。数据适用于 2010 年至 2019 年的历史时期。
竞争格局和癌症支持护理产品市场份额分析
癌症支持护理产品市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对癌症支持护理产品市场的关注有关。
报告中涉及的主要参与者包括安进公司、杨森制药公司（强生服务公司子公司）、辉瑞公司、APR、诺华公司、罗氏公司、Acacia Pharma Group Plc、百特、拜耳公司、Helsinn Healthcare SA、Heron Therapeutics、Inc.、Kyowa Kirin Co.、Ltd.、Acrotech Biopharma、Spectrum Pharmaceuticals、Inc.、Oxford Pharmascience Ltd、默克夏普和多姆公司（默克公司的子公司）、Teva（Teva Pharmaceutical Industries Ltd. 的子公司）、Tersera Therapeutics Llc.、迈兰公司、太阳制药工业有限公司以及其他国内和欧洲参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球范围内的许多产品批准和协议也由公司发起，这也加速了癌症支持护理产品市场的发展。
例如，
- 2019年10月，Heron Therapeutics, Inc.宣布美国食品药品监督管理局批准了Heron的CINVANTI（阿瑞吡坦）注射乳剂补充新药申请（sNDA）。此项批准有助于增强公司在美国市场的影响力。
- 2020 年 1 月，诺华公司宣布收购 Medicines Company。此次收购为该公司扩大其全球业务提供了新的机会。同时，它还帮助升级了公司的产品组合。
市场参与者的合作、合资和其他策略正在增强公司在癌症支持护理产品市场的影响力，这也为组织的增长速度带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DRUG TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 REGULATORY
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING CANCER BURDEN WORLDWIDE
5.1.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
5.1.3 GROWING GERIATRIC POPULATION
5.1.4 RISING NUMBER OF PRODUCT APPROVAL
5.1.5 RISING EXPENDITURE ON HEALTHCARE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER SUPPORTIVE DRUGS
5.2.2 LACK OF EARLY DETECTION
5.3 OPPORTUNITIES
5.3.1 ACQUISITION AND AGREEMENT BY MAJOR PLAYERS
5.3.2 RISING PRODUCT LAUNCHES
5.3.3 GROWING R&D ACTIVITIES
5.4 CHALLENGES
5.4.1 STRINGENT REGULATION POLICY
5.4.2 PATENT EXPIRY OF DRUGS
6 COVID-19 IMPACT ON EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS)
7.2.1 LONG ACTING FILGRASTIM
7.2.2 FILGRASTIM
7.2.3 LENOGRASTIM
7.3 ERYTHROPOIETIN STIMULATING AGENTS (ESA’S)
7.3.1 EPO-Α/Β
7.3.2 DPO
7.3.3 CERA
7.3.4 EPO-Κ
7.4 OPIOID ANALGESICS
7.4.1 FENTANYL
7.4.2 METHADONE
7.4.3 TRAMADOL
7.4.4 OTHERS
7.5 MONOCLONAL ANTIBODIES
7.6 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
7.6.1 OTC NSAIDS
7.6.1.1 ASPIRIN
7.6.1.2 IBUPROFEN
7.6.1.3 NAPROXEN SODIUM
7.6.2 PRESCRIPTION NSAIDS
7.6.2.1 CELECOXIB
7.6.2.2 DICLOFENAC
7.6.2.3 INDOMETHACIN
7.6.2.4 KETOROLAC
7.6.2.5 MELOXICAM
7.6.2.6 NABUMETONE
7.6.2.7 NAPROXEN
7.6.2.8 OXAPROZIN
7.6.2.9 PIROXICAM
7.6.2.10 SULINDAC
7.6.2.11 OTHERS
7.7 BISPHOSPHONATES
7.7.1 ZOLEDRONIC ACID OR ZOLEDRONATE
7.7.2 DISODIUM PAMIDRONATE
7.7.3 IBANDRONIC ACID OR IBANDRONATE
7.7.4 SODIUM CLODRONATE
7.8 ANTI-EMETICS
7.8.1 APREPITANT
7.8.2 DEXAMETHASONE
7.8.3 DOLASETRON
7.8.4 GRANISETRON
7.8.5 ONDANSETRON
7.8.6 PALONOSETRON
7.8.7 PROCHLORPERAZINE
7.8.8 ROLAPITANT
7.8.9 OTHERS
7.9 ANTIHISTAMINES
7.9.1 HYDROXYZINE
7.9.2 DIPHENHYDRAMINE
7.9.3 OTHERS
7.1 OTHERS
8 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE
8.1 OVERVIEW
8.2 BRANDED
8.2.1 NEULASTA
8.2.2 ARANESP
8.2.3 PROLIA
8.2.4 XGEVA
8.2.5 EPOGEN
8.2.6 EPREX
8.2.7 NEUPOGEN
8.2.8 OTHERS
8.3 GENERICS
9 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 LUNG CANCER
9.3 BREAST CANCER
9.4 PROSTATE CANCER
9.5 LIVER CANCER
9.6 BLADDER CANCER
9.7 LEUKAEMIA
9.8 MELANOMA
9.9 OVARIAN CANCER
9.1 OTHER CANCERS
10 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.2.1 ACUTE CARE HOSPITALS
10.2.2 LONG-TERM CARE HOSPITALS
10.2.3 NURSING FACILITIES
10.3 CLINICS
10.4 HOSPITALS & ACADEMIC INSTITUTIONS
10.5 OTHERS
11 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACIES
11.3 RETAIL PHARMACIES
11.4 COMPOUNDING PHARMACIES
12 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY GEOGRAPHY
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 SWITZERLAND
12.1.7 NETHERLANDS
12.1.8 RUSSIA
12.1.9 TURKEY
12.1.10 REST OF EUROPE
13 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT
15 COMPANY PROFILES
15.1 AMGEN INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 PFIZER INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOVARTIS AG
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 ACACIA PHARMA GROUP PLC
15.5.1 COMPANY SNAPSHOT
15.5.2 PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ACROTECH BIOPHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 APR
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 BAXTER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 HELSINN HEALTHCARE SA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 HERON THERAPEUTICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 KYOWA KIRIN CO., LTD.
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 MYLAN N.V.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENTS
15.16 OXFORD PHARMASCIENCE LTD
15.16.1 COMPANY SNAPSHOT
15.16.2 TECHNOLOGY PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SPECTRUM PHARMACEUTICALS, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 TERSERA THERAPEUTICS LLC
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 MORTALITY DUE TO CANCER, AGES 85+, IN THE U.S.
TABLE 3 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2020-2028 (USD MILLION)
TABLE 4 EUROPE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 8 EUROPE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE MONOCLONAL ANTIBODIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 13 EUROPE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 EUROPE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 19 EUROPE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 21 EUROPE OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE 2020-2028 (USD MILLION)
TABLE 23 EUROPE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 EUROPE GENERICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2020-2028 (USD MILLION)
TABLE 27 EUROPE LUNG CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE BREAST CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE PROSTATE CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE LIVER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE BLADDER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE LEUKAEMIA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE MELANOMA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE OVARIAN CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE OTHER CANCERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 37 EUROPE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 39 EUROPE CLINICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE HOSPITALS & ACADEMIC INSTITUTIONS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 EUROPE HOSPITAL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 EUROPE RETAIL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 EUROPE COMPOUNDING PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
TABLE 47 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 48 EUROPE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 49 EUROPE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 53 EUROPE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 54 EUROPE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 EUROPE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 56 EUROPE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 EUROPE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 60 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 61 EUROPE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 GERMANY GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 65 GERMANY OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 66 GERMANY ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 67 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 68 GERMANY OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 69 GERMANY PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 70 GERMANY BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 GERMANY ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 72 GERMANY ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 73 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 GERMANY BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 76 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 GERMANY HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 GERMANY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 80 FRANCE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 81 FRANCE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 82 FRANCE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 83 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 84 FRANCE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 FRANCE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 FRANCE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 FRANCE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 FRANCE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 89 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 FRANCE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 92 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 93 FRANCE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 FRANCE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.K GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 97 U.K OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 U.K ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 U.K NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 U.K OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 U.K PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 102 U.K BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 103 U.K ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 104 U.K ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 105 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 U.K BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 108 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 109 U.K HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 U.K CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 111 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 112 ITALY GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 113 ITALY OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 114 ITALY ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 115 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 116 ITALY OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 117 ITALY PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 118 ITALY BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 119 ITALY ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 120 ITALY ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 121 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 ITALY BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 ITALY HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ITALY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 128 SPAIN GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 129 SPAIN OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 130 SPAIN ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 131 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 132 SPAIN OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 133 SPAIN PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 134 SPAIN BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 135 SPAIN ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 136 SPAIN ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 137 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 SPAIN BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 139 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 140 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 141 SPAIN HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 SPAIN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 143 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)
TABLE 144 SWITZERLAND GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 145 SWITZERLAND OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 146 SWITZERLAND ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 147 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 148 SWITZERLAND OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION) (USD MILLION)
TABLE 149 SWITZERLAND PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 150 SWITZERLAND BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 151 SWITZERLAND ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 152 SWITZERLAND ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 153 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 SWITZERLAND BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 156 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 157 SWITZERLAND HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 158 SWITZERLAND CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 159 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)
TABLE 160 NETHERLANDS GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 161 NETHERLANDS OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 162 NETHERLANDS ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 163 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 164 NETHERLANDS OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION) (USD MILLION)
TABLE 165 NETHERLANDS PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 166 NETHERLANDS BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 167 NETHERLANDS ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 168 NETHERLANDS ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 169 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 NETHERLANDS BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 172 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 173 NETHERLANDS HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 174 NETHERLANDS CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 175 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 176 RUSSIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 177 RUSSIA OPOID ANALGESIC IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 178 RUSSIA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 179 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 180 RUSSIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 181 RUSSIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 182 RUSSIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 183 RUSSIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 184 RUSSIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 185 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 186 RUSSIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 187 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 188 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 189 RUSSIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 190 RUSSIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 191 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 192 TURKEY GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 193 TURKEY OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 194 TURKEY ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 195 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 196 TURKEY OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 197 TURKEY PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 198 TURKEY BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 199 TURKEY ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 200 TURKEY ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 201 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 TURKEY BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 204 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 205 TURKEY HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 206 TURKEY CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 207 REST OF EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
图片列表
LIST OF FIGURES
FIGURE 1 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 2 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 10 GROWING CANCER BUREN WORLDWIDE IS EXPECTED TO DRIVE THE EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET
FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 14 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES (WORLD) IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 15 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020
FIGURE 16 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020-2028 (USD MILLION)
FIGURE 17 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 18 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 19 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, 2020
FIGURE 20 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020
FIGURE 24 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020-2028 (USD MILLION)
FIGURE 25 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, CAGR (2021-2028)
FIGURE 26 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 27 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020
FIGURE 28 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 29 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 30 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 32 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 33 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 34 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020)
FIGURE 36 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020)
FIGURE 37 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 38 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028)
FIGURE 40 EUROPE CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
